Amgen Agrees to $71 Million Settlement over Enbrel & Aranesp Promotion Save

Based on potentiallly off-label promotion of blockbuster drugs Aranesp and Enbrel, Amgen has agreed to a $71 million settlement with 48 states and the District of Columbia.

The reported allegations included promotion of non-FDA approved dosing frequencies for anemia, and encouraging its use to treat anemia caused by cancer without FDA approval. Additionally, Amgen was accused of promoting Enbrel for mild plaque psoriasis (only approved for moderate to severe plaque psoriasis). As part of the settlement, Amgen has not admitted wrong-doing or liabiility.